schizophrenia clinical development

LONDON, UK: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announced that Monument Therapeutics Limited has completed a £1.0 million fundraise and announced a further £0.5 million grant funding for the development…